http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
철도선로변 금속체의 전위분포 해석에 의한 접지설계 기준 수립
김도원(D.W. Kim),박종원(J.W. Park),박윤철(Y.C. Park),호명재(M.J. Ho),심건보(K.B. Shim) 한국철도학회 2014 한국철도학회 학술발표대회논문집 Vol.2014 No.10
전기철도 구간에서 전기동력차 및 전원공급 설비의 증가에 따라 차량 운행중의 정상상태 부하전류와 지락고장 등에 의한 고장전류의 증가에 따라 철도시설물에 이상전압으로부터 안전을 확보하고자 하는 대책으로 공통접지방식을 시행하고 있다. 그러나 시공의 현장에서 철도선로로부터 일정한 거리 또는 교량의 하부 등에 시설되는 울타리 등의 금속체에 대한 시공은 현장의 여건상 어려움이 많이 발생하고 있다. 따라서 본 연구에서는 철도선로의 연변에 시설되는 금속체에 대하여 차량 운행중의 정상상태와 고장상태에서 발생하는 전위분포를 측정하는 시험과 대지저항률의 변화에 따른 전위분포의 시뮬레이션을 통하여 인체에 미치는 영향을 검토하여 안전을 확보할 수 있는 접지설계 기준을 수립하고자 하였다. The power supply system of electric railway is consist of many electric facilities such as overhead contact line, power supply system, a signaling tract circuits, train control system and train communication system etc. Electric grounding systems are adopted for the protections of the human being and the damage of equipment from the overcurrent and the overvoltage by electrical accidents. In this paper, we deal with the standard of common grounding system for electrical railway system. Especially, grounding design for the metal structures in the electric railway. For the proposed paper, we tested the potential distribution of the metal structure in the electric railway system at the fields. And we analyzed the data from field tests and computer simulations for the effectiveness of the common grounding system in the electric railway system.
김태운,홍성욱,김호명,원태웅,하지형 한국식품과학회 2024 식품과학과 산업 Vol.57 No.2
Modern society is in the era of the bio economy, and it is predicted that the value of bio materials will become more prominent in the future. In particular, the necessity and importance of national sovereignty over biological resources is emphasized with the adoption of the Protocol on Access and Benefit Sharing of Biological Resources for the purpose of the Convention on Biological Diversity (2010). The importance of securing differentiated biological resources and information as source materials for the bio industry is increasing. As a research institute leading kimchi R&D, the World Institute of Kimchi strives to scientifically prove the excellence of kimchi, and the results of its efforts are systematically compiled in the “Bank of Kimchi Resources and Information (BKRI).” In this article, an efficient information system is introduced, from the acquisition, storage, and distribution system of physical resources integrated and managed by BKRI to the disclosure of information resources.
Lactiplantibacillus plantarum WiKim0125 균주의 발효 최적화 및 스케일 업 공정 개발
김영열(Yeong Yeol Kim),김슬비(Seulbi Kim),김정환(Jung Hwan Kim),김호명(Ho Myeong Kim) 한국유산균프로바이오틱스학회 2023 Current Topic in Lactic Acid Bacteria and Probioti Vol.9 No.1
In probiotics production, lactic acid bacteria (LAB) are cultured on a large scale to achieve efficient processing through fermentation optimization and scale-up. In this Current study, the LAB strain Lactiplantibacillus plantarum WiKim0125 was isolated from kimchi and optimized the production. The optimization strategy for cultivating L. plantarum WiKim0125 consisted of investigating media components, selecting physiochemical conditions to enhance productivity, and scaling up for pilot-scale production. Each process condition was evaluated based on substrate consumption, lactic acid production, and viable cell yield. As a result, the final viable cell and lactic acid yield of L. plantarum WiKim0125 increased by 38.6% and 19.4%, respectively. This study provides an overview of fermentation optimization and scale-up processes for the industrial application of L. plantarum WiKim0125.
지속성 외래 복막투석 환자에서 고용량(10,000 IU) Epoetin alfa의 효과에 대한 교차 연구
도정호 ( Jung Ho Do ),김대중 ( Dae Joong Kim ),최소연 ( So Yeon Choi ),도연실 ( Yeon Sil Do ),장은희 ( Eun Hee Jang ),백현정 ( Hyun Jeong Baek ),김정인 ( Jung In Kim ),여호명 ( Ho Myoung Yeo ),최성철 ( Sung Chul Choi ),이정은 ( Ju 대한내과학회 2006 대한내과학회지 Vol.71 No.5
Background: Recombinant human erythropoietin (rHuEPO) is an essential and well-established treatment for renal anemia. Rcently, clinicians have moved toward administration of high dose rHuEPO to reduce the inconvenience and time efficient. We aimed to determine whether high dose subcutaneous (SC) epoetin alfa is as efficient and safe as the usual dose for treating anemia in continuous ambulatory peritoneal dialysis (CAPD) patients. Methods: Twenty-four patients on CAPD were randomly assigned to a high-usual dose group (n=12) and an usual-high dose group (n=12) with a variable interval for 48 weeks. Patients received 10 times treatments by scheduled visiting during Period I lasting 24 weeks and received 4 times treatments by scheduled visiting in Period II lasting 24 weeks by cross-over. The high dose was 10,000 IU and the usual dose was 4,000 IU epoetin alfa regimen. If hematocrit was out of the targeted range, 30~39%, the interval of epoetin alfa was changed within 50% of the previous interval. Results: Fifteen patients, out of 24, completed the study (8 patients in the high-usual dose group; 7 patients in the usual-high dose group). Mean hemoglobin levels at randomization and after 12, 24, 36 and 48 weeks were 10.8±1.1, 11.5±0.9, 11.5±1.5, 11.4±1.5, 11.5±0.8 g/dL, respectively, in high-usual dose group compared with 11.2±0.8, 11.4±1.2, 11.2±0.9, 11.2±1.4, 11.4±0.9 g/dL, respectively, in usual-high dose group. The mean weekly epoetin alfa dosages at randomization and after 12, 24, 36 and 48 weeks were 83.6±38.1, 87.1±35.8, 89.4±34.2, 60.1±25.1, 62.8±30.7 IU/kg/week, respectively, in high-usual dose group compared with 69.8±31.6, 64.9±12.2, 69.9±46.1, 78.8±29.3, 75.9±16.4 IU/kg/week, respectively, in usual-high dose group. No statistically significant differences between the two groups were apparent for hemoglobin levels or mean weekly epoetin alfa dosages. Treatment interval at Period I and Period II were 13.3±5.3, 8.2±4.3 days in high-usual dose group compared with 7.0±2.5, 13.4±4.0 days in usual-high dose group with statistically significant differences. Treatment interval in high dose was about two times as longer as usual dose. Adverse events were generally mild and transient, and pain on injection site following subcutaneous administration was rarely reported. Conclusions: This study demonstrates that epoetin alfa 10,000 IU is as efficient and safe as 4,000 IU with a similar weekly dose in CAPD patients. Epoetin alfa 10,000 IU administration can reduce frequency of injections by about one half.(Korean J Med 71:527-534, 2006)